RESEARCH TRIANGLE PARK, NC − From $100 million specialty treatments to $10 billion blockbusters, pharma and biotech companies are searching for ways to better manage their drugs in a marketplace that continues to grow more competitive.

Three new reports from business intelligence firm Cutting Edge Information aim to provide commercialization teams, brand managers, sales leaders and marketing executives the tools they need to make smart decisions as early as possible about products across a range of sizes.

“Together, these three reports discuss the structure, strategy and resource allocation needed to make every molecule reach its potential,” says Jason Richardson, President of Cutting Edge Information. “There are similarities between niche, mid-market and blockbuster products. But there are also a lot of specific rules that different-sized products and products in different therapeutic areas must follow. Those rules are what we were trying to establish.”

* “Small and Specialty Drug Branding: Tapping Niche Market Potential” looks at products with potential market size of up to $500 million in annual sales. More information available at: http://www.cuttingedgeinfo.com/pharmaBrandResources/index_small_brands.htm .

* “Marketing Mid-Tier Pharmaceutical Brands: Winning Resources for Near-Blockbusters” examines drugs with a projected maximum annual revenue of $500 million to $1 billion. More information at: http://www.cuttingedgeinfo.com/pharmaBrandResources/index_midlevel_brands.htm .

* “Blockbuster Pharmaceutical Launches: Brand Resource Allocation” analyzes brands with a potential market size of over $1 billion in annual sales. More information at: http://www.cuttingedgeinfo.com/pharmaBrandResources/index_blockbusters.htm .

Some of the companies and organizations included in the reports are Abbott Laboratories, Allergan, Amgen, AnorMED, AstraZeneca, Berlex, Biovail, Bristol-Myers Squibb, Cubist, CV Therapeutics, Dendreon, Eli Lilly, Genzyme, Gilead, Human Genome Sciences, Johnson & Johnson, Merck KGaA, Millennium Pharmaceuticals, Novartis, Novo Nordisk, Novopharma, Nycomed, Organon, OSI Pharmaceuticals, Pfizer, Procter & Gamble, Roche, Salix, Sanofi-Aventis, Schering-Plough, Serono, Shire Pharmaceuticals, TAP Pharmaceuticals, and Tercica.

The three reports include 574 pages of strategic and tactical analysis, with more than 1,200 metrics and 300 charts and diagrams. To view a quick summary of these reports, savable on your desktop, please visit http://www.cuttingedgeinfo.com/ . For more information about the blockbuster, mid-market and niche drug commercialization and resource reports, contact analyst Elio Evangelista at 919-433-0214 or Elio_Evangelista@cuttingedgeinfo.com .

For consulting queries or to submit an RFP, please contact Jason Richardson at 919-433-0201 or jason_richardson@cuttingedgeinfo.com .

<-- Back to the News Page

<-- Back to the Cutting Edge Information home page